Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Oritavancin Phosphate in Preparation of Drugs for Prevention and Treatment of Bovine Infectious Rhinotracheitis

A technology for oritavancin phosphate and rhinotracheitis, applied in the field of medicine, can solve problems such as hidden safety hazards, inability to remove viruses, differential diagnosis and the like

Active Publication Date: 2021-09-10
DAIRY CATTLE RES CENT SHANDONG ACADEMY OF AGRI SCI +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Individuals after immunization with inactivated vaccines cannot be differentially diagnosed with naturally infected individuals, so it will bring certain obstacles to the eradication of bovine infectious rhinotracheitis
Traditional attenuated vaccines have the phenomenon of virulence returning to strength, and there are certain safety hazards
The most important thing is that bovine infectious rhinotracheitis virus is an intracellular proliferating virus, and inactivated vaccines cannot remove the virus in the body, but can only prevent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Oritavancin Phosphate in Preparation of Drugs for Prevention and Treatment of Bovine Infectious Rhinotracheitis
  • Application of Oritavancin Phosphate in Preparation of Drugs for Prevention and Treatment of Bovine Infectious Rhinotracheitis
  • Application of Oritavancin Phosphate in Preparation of Drugs for Prevention and Treatment of Bovine Infectious Rhinotracheitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1 Bovine Infectious Rhinotracheitis Virus TCID 50 determination of

[0042] MDBK cells (preserved by the Dairy Cattle Research Center of Shandong Academy of Agricultural Sciences) were digested with 1 × 10 cells per well. 5 Cells / mL were seeded into 96-well cell culture plates at 37°C, 5% CO. 2 After culturing into a monolayer of cells in a cell incubator, discard the cell growth solution in the well, and serially diluted the virus dilution solution of bovine infectious rhinotracheitis virus (preserved by the Dairy Cattle Research Center of Shandong Academy of Agricultural Sciences) by 10 times (dilutions respectively). is 10 -1 ~10 -10 ) were seeded in a 96-well plate full of monolayer cells, 100 μL per well, and placed in 37°C, 5% CO. 2 Continue to culture in the incubator, and observe the CPE (cytopathic effect) of the cells daily, and record the number of cytopathic wells in detail. At the same time, a normal cell control group and a blank control gro...

Embodiment 2

[0053] Example 2 Toxicity test of oritavancin phosphate on MDBK cells:

[0054] MDBK cells are susceptible cells for bovine infectious rhinotracheitis virus. Therefore, the cytotoxicity of oritavancin phosphate on MDBK cells was first detected, and the specific experimental steps were as follows:

[0055] (1) Inoculate 100 μL of cells (5000 MDBK cells / well) in a 96-well plate.

[0056] (2) After culturing for about 12 hours, proceed to the next step of dosing analysis. Discard the culture medium, add 100 μL of 2% FBS DMEM containing different drug concentrations (50 μM as the starting concentration, 25 μM, 12.5 μM, 6.25 μM, 3.125 μM and other 9 concentrations) in each well. Do 3 parallels for each concentration. Control wells at the same time: add 100 μL of 2% FBS DMEM medium containing 0.9% DMSO. Zero well: Do not plate cells.

[0057] (3) At 37°C, 5% CO 2 After 48 hours of culture under the conditions, the medium in the wells was discarded. Wash twice with 100 μL PB...

Embodiment 3

[0062] Example 3 Inhibition experiment of oritavancin phosphate on bovine infectious rhinotracheitis virus:

[0063] (1) Inoculate 1 × 10 in each well of a 96-well plate 4 MDBK cells, 37°C, 5% CO 2 overnight in an incubator;

[0064] (2) Discard the medium and add 100μL of 100TCID to each well 50 Bovine Infectious Rhinotracheitis Virus Dilution Solution (with 2% FBS DMEM cells, add the virus dilution solution, according to the initial concentration of 50 μM, twice the concentration gradient dilution dosing, 5% CO 2 cultivated in an incubator;

[0065] (3) After 48 hours, operate according to the instructions of the CCK-8 kit, and use a microplate reader to measure the OD value at 450 nm.

[0066](4) Analysis of data, virus inhibition rate (%)=(D450nm value of drug treatment group-D450nm value of virus control group) / (D450nm value of normal cell control group-D450nm value of virus control group)×100%, obtained by GraphPad Prism5 software The half effective concentration ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of oritavancin phosphate in the preparation of a drug for preventing and treating bovine infectious rhinotracheitis. Oritavancin phosphate can inhibit and kill bovine infectious rhinotracheitis in an in vitro MDBK cell model The virus can effectively inhibit the invasion and replication of bovine infectious rhinotracheitis virus, and has low cytotoxicity. It also lays the foundation for the development of highly effective and specific anti-bovine infectious rhinotracheitis virus drugs and provides a new perspective.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of oritavancin phosphate in the preparation of a medicine for preventing and treating bovine infectious rhinotracheitis. Background technique [0002] The information disclosed in this Background section is only for enhancement of understanding of the general background of the invention and should not necessarily be taken as an acknowledgement or any form of suggestion that this information forms the prior art already known to a person of ordinary skill in the art. [0003] Infectious bovine rhinotracheitis (IBR) is an acute, febrile and contact infectious disease caused by Infectious bovine rhinotracheitis virus (IBRV). It is characterized by runny nose, upper respiratory tract and trachea, and mucosal inflammation. In the early 1950s, infectious bovine disease with symptoms of rhinotracheitis first appeared in some ranches in Colorado, USA, and the clinical symptoms of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/14A61P31/22
CPCA61K38/14A61P31/22
Inventor 楚会萌程凯慧杨宏军任亚初解晓莉张亮于志君
Owner DAIRY CATTLE RES CENT SHANDONG ACADEMY OF AGRI SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com